

Index

a

- access control 199, 209
- accounting methods
 - cost accounting 338–347
 - cost positions of fermentation 335–336
 - cost positions of filling and packaging 338–341
 - cost positions of purification 338–339
 - profit and loss accounting 347–349
- accuracy 114, 116, 207, 252, 307, 308, 346, 359, 432, 433, 446
- action of drugs in humans
 - pharmacodynamics 149–152
 - pharmacokinetics 145–149
- active pharmaceutical ingredient (API) 37, 40, 97, 106, 184, 193–195, 221, 234, 239, 266, 276, 277, 296, 332, 333, 370, 394, 398, 405, 418, 422
 - manufacturing plant 266
- active vaccination 12, 22
- activity assays 111, 112
- actual accounting 327–328
- acute toxicity 156
- adenine 24, 30
- adenosine triphosphate (ATP) 20
- adherent cell cultures 57–60
- adult rheumatoid arthritis 245–246
- advanced-therapy medicinal products (ATMPs) 232
- adverse drug reaction (ADR) 165
- adverse events 165, 167, 168
- affinity chromatography 69, 72, 82, 84–86, 91, 95, 107, 123
- ALCOA principle 447
- allogeneic cell therapy 15
- American College of Rheumatology (ACR) 244, 245
- American College of Rheumatology criteria (ACR20) 245, 247
- amino acid analysis 116
- analytical chromatography 81, 123–125
- analytical criterion 61
- analytical testing 6, 62, 103, 105, 159, 195, 209, 212, 394
- analytics role in biotechnology 103–105
- annuity 363, 367
- antibiotics 10, 11, 16, 17
- antigen 12, 27, 112, 121, 122, 149, 233
- antigen-binding fragment 27
- ANVISA 236
- aqua purificata (AP) 254, 277, 278, 280–282, 284, 288
- aqua valde purificata (AVP) 277
- area under the curve (AUC) 124, 148
- ATTRACT study 245
- audits 177, 178, 186–187, 234, 377, 378, 401
- authorities of growth markets 235–236
- automation 204, 208, 251, 269, 280–281, 293–294, 308, 335, 359, 364, 415, 416, 429, 432, 435, 437, 446, 447

b

baby hamster kidney (BHK) 45, 46
 bacteria 12, 17, 22, 23, 25, 313, 44, 45, 54, 70,
 90, 91, 109, 129, 130, 135, 276, 280, 285, 427
 bacteriophages 22–23
 baseline separation 124
 batch and continuous processes 50–53
 batch-to-batch cleaning 202, 371
 bindingness of regulations 226–227
 bioburden test 130
 biochemical mechanism of action 112
 biological cells 16, 17, 23, 146
 biological effect 109, 111, 163, 316
 Biological License Application (BLA) 241
 biological substances 285, 295, 316
 biology
 – cells and microorganisms
 – – general features 17
 – – metabolism 19–21
 – – protein biosynthesis 23–25
 – – reproduction and aging 21–22
 – – structure and types of 17–19
 – – viruses and bacteriophages 22–23
 – molecular building blocks
 – – lipids 31
 – – nucleic acids 29–30
 – – polysaccharides 30–31
 – – proteins 25–29
 biosuspensions 71
 biotechnological manufacturing processes
 – capital costs 333–335
 – operating costs 335–338
 biotechnological pharmaceuticals 7, 103, 183,
 319
 biotechnology, role of analytics in 3, 6, 7, 10,
 12, 22, 23, 25, 35–37, 103–105, 143, 195, 214,
 239, 240, 275, 294, 296, 333
 blotting 121
 bovine spongiform encephalopathy (BSE) 42,
 137
 Brazilian Agência Nacional de Vigilância
 Sanitária 236
 building law 225, 316, 317–318
 Business Process Model and Notation (BPMN)
 methods 419

business processes 413, 415, 418, 419, 423,
 444, 446

c

capacity limit 372
 capacity planning 369–372
 capacity usage 349, 370, 372, 376, 409
 capillary electrophoresis (CE) 118, 120
 capital commitment 351, 355, 357
 capital costs 326, 332, 333–335
 capital demand 351
 capital recovery factor 367
 capital value method 366
 carcinogenicity 156
 cell bank
 – expression systems 43
 – manufacturing and storage of 46–48
 – microbial systems 44–45
 cell integrity criterion 61
 cell separation 65, 73–80
 Center for Biologics Evaluation and Research
 (CBER) 219, 228–230, 233
 Center for Drug Evaluation and Research
 (CDER) 219, 228, 229, 233
 Certificate of Compliance 182, 211, 212
 chamber-filter press 74, 79
 change risks 311
 chemical ionization (CI) 126
 China 228, 235–236
 – National Medical Products Administration
 (NMPA) 236
 Chinese hamster ovary (CHO) 45, 46, 56
 chromatography 72
 – gels 42, 67, 69, 91, 92, 184, 195, 333, 335,
 406, 407
 – processes 39, 78, 81
 chronic toxicity 156
 circular dichroism 131
 clean steam 63, 136, 205, 254, 275, 281, 282,
 287, 308
 clean utilities 209, 212, 275–286, 308
 clean-rooms
 – configuration 199
 – floors, walls, and ceilings finishing 291
 – HVAC installations 292

- qualification 293
 - separation of zones 289–291
 - cleaning in place (CIP) systems 57, 63, 208, 254, 273, 274, 280, 281, 287, 288
 - cleaning out of place (COP) 287
 - cleaning validation 206, 207, 273, 371
 - clearance 147
 - client obligations 311, 312
 - Clinical Trials Directive (CTD) 194, 237, 241
 - Clinical Trials Directive (Directive 2001/20/EC) 194, 241
 - Code of Federal Regulation (CFR) 219, 221, 226, 227, 230
 - codon usage 25
 - commercial risks 311
 - Commission Directive 91/356/EEC 232
 - Committee for Advanced Therapies (CAT) 232
 - Committee for Medicinal Products for Human Use (CHMP) 231
 - Committee for Medicinal Products for Veterinary Use (CVMP) 231
 - Committee for Orphan Medicinal Products (COMP) 231
 - Common Technical Document (CTD) 237, 241
 - comparability protocol 216
 - computer validation 208–209, 294, 305
 - computer-based systems 208
 - concentration/isolation 65
 - conceptual plant layout 257–261
 - construction
 - engineering project 301–303
 - phase of construction 303
 - contaminations 69, 71, 81, 90, 109, 135–137, 198–200, 256, 264–266, 279, 286, 288, 289, 293
 - continuous cell lines 21, 47
 - contractual agreements 311, 376, 377–382
 - contract manufacturer 375, 376, 384
 - control of defective products 176, 182
 - cooperation pathways 413, 421–423
 - cosmetic defects 101
 - cost accounting 327, 328, 331, 332, 338–348
 - cost calculation
 - actual accounting 327–328
 - biotechnological manufacturing processes 332–338
 - cost type, cost center, and cost unit 331
 - direct costs 328
 - fixed costs 329–330
 - indirect costs 328
 - profit and loss accounting 328
 - relevant and irrelevant costs 330
 - variable costs 329–330
 - cost inertia 329
 - cost optimization 227
 - cost planning and control 300
 - cost risks 311, 323
 - cost savings 175, 261
 - cost-distribution sheets 345
 - Creutzfeldt–Jakob disease (CJD) 137
 - critical path 306
 - critical process parameters 204, 304, 383, 431
 - cross-contamination 198, 201–203, 256, 259, 271, 273
 - cross-flow filtration 78
 - crystalline fragment 27
 - crystallization 72, 81, 293
 - C-terminus 25
 - current good manufacturing practice (CGMP) 191
 - regulations 219, 220
 - rules 259
- d**
- data accessibility and readability 209
 - data analytics 430, 437
 - data safety 208
 - decision processes 355–359, 445
 - decoupling 40, 372
 - Define-Measure-Analyze-Improve-Control (DMAIC) 392
 - cycle 394
 - process 392
 - demand-to-order 419–421
 - depreciation amount 333, 334
 - design control 178, 189
 - desorption 76, 77, 81, 126, 127
 - diafiltration 39, 65, 72, 79, 95, 97, 276

- differential scanning calorimetry (DSC)
 - 131–132
 - differentiating overhead calculation 344
 - digital maturity 413, 427, 429, 435–440, 442
 - digital transformation 413, 428, 438, 444–446
 - digitalization
 - digital maturity 435–440
 - digital transformation 444–446
 - GMP environment 446–449
 - integration and IT architecture 440–444
 - operational and digital perspective 428–435
 - diligent business-process modeling 419
 - direct costs 328, 338, 344, 348, 349
 - disease-modifying antirheumatic drugs (DMARDs) 244, 246
 - DNA/RNA sequencing 128, 129
 - documentation
 - good manufacturing practice 209–210
 - pharmaceutical area 180–181
 - dose-dependent side-effects 149, 150
 - dose-finding studies 158
 - drug approval 225, 228, 232, 234, 236, 239, 241–242
 - drug dossier 132, 196, 206, 214, 216, 241, 390
 - drug life cycle 321
 - break-even point 323
 - development effort 324
 - fast-track status 324
 - life-cycle curve 322
 - life-cycle management 324
 - off-label use 325
 - patent protection 323
 - pharmaceutical market 321–322
 - phases of 323
 - pricing 325
 - target profile 325
 - time to market 324
 - drug product manufacturing 40–41
 - drug safety
 - causes and classification of side-effects 165–167
 - measures upon incidence of adverse reactions 168–169
 - pharmacovigilance 167–168
 - drug study
 - clinical study 157–162
 - pre-clinical study 155–157
 - drug substance manufacturing 38–40
 - dry weight 25
 - dynamic payback time 363, 367–368
- e**
- effective dose (ED50) 150, 152
 - electronic signature 208, 230, 448
 - electrophoresis 115, 117–120, 121, 129
 - Enbrel® 244–245
 - endotoxins 54, 70, 109, 129–130, 276
 - engineering project
 - commissioning 303–306
 - construction 301–303
 - contractors role and selection 310
 - contracts and scope changes 310–314
 - critical process parameters 304
 - expert groups 309
 - planning 300–301
 - principal steps 299–300
 - qualification 303–306
 - successful execution 314–315
 - validation 303–306
 - engineering runs 306
 - enhanced design review 304
 - enterprise recipe management (ERM) system 438
 - enterprise resource planning (ERP) 423, 436, 437, 441
 - environmental law 264, 316–317
 - environmental monitoring 42, 103, 135, 187, 328
 - enzyme-linked immunosorbent assay (ELISA) 122–123
 - equipment cleaning 50, 63, 88, 201, 209, 251, 253, 260, 263, 278, 280, 286–288
 - EU GMP guideline 192–193
 - EU Guidelines for Good Manufacturing Practice 193
 - EudraLex 192, 194, 232, 233
 - eukaryotic cells 17, 19, 21, 25
 - European Directorate for the Quality of Medicines (EDQM) 232, 234

European Medicines Agency (EMA) 227, 230–233, 236, 239, 241, 243, 447

execution risks 311

expanded-bed adsorption (EBA) 78

expansion facilities planning 260

expert groups 234, 309

expression strength 25, 49

expression system 16, 43–45, 47, 48, 52, 55, 60, 65, 70, 375

external audits 177, 186

external contamination 198–201

external manufacturing 356, 359, 369, 375, 376, 385

extracellular expression 44, 45

extraction 13, 72, 76, 89–90, 441

ex vivo gene therapy 14

f

facility design

- automation 293–294
- basic principles 251–254
- clean utilities 275–286
- clean-rooms 288–293
- cost 295–296
- equipment cleaning 286–288
- GMP-Compliant Plant Design 254–267
- know-how and intellectual property protection 297
- language and culture 298
- logistics 297
- market access 297
- permitting 296
- personnel 296
- plant utilities 283–285
- production plant 267–275
- QC laboratories 295
- risks 297
- synergies with existing facilities or units 296–297
- waste management 285–286

facility engineering

- building law 317–318
- health, safety, and environmental law 316–317

failure correction and prevention 177

failure mode and effect analysis (FMEA) 184, 400

fast-atom bombardment (FAB) 27, 126, 127

fermentation 132

- overview of 63–64
- principles
- – batch and continuous processes 50–53
- – cell growth and product expression 49–50
- – goals 48
- – mammalian cells and microorganisms 55–56
- – requirements 49
- – sterility and sterile technologies 53–55
- raw materials and processing aids
- – nutrient media 61–62
- – water, gases, and pH adjustment 62–63
- technologies and equipment
- – adherent cell cultures 57–60
- – in suspension culture 56–57
- – transgenic systems 60–61

fermentation capacity 369, 370

fermentation titer 41, 370

Filgrastim 153

filter-cake 79

finance-oriented factors 355

finished product 38, 101, 104, 106, 134, 139, 387, 397

fixed costs 101, 328–330, 348, 349, 406–409

fixed investments 353

flexible and fixed piping 273–274

floors, walls, and ceilings finishing 291

Food and Drug Administration (FDA) 214, 217, 219–221, 227, 228–231, 233, 236, 239, 240, 298, 324, 447

formulation and packaging 134–135, 335

fractal and integrated configuration 271–272

Freedom of Information Act (FOIA) 230

freeze-drying 38, 98–99, 452

full-scale runs 8

g

gene expression 18, 24

general SOPs 180

genome 22, 23, 24, 29, 30, 44, 267

German Authorities 233–234
 Gerstmann–Straussler syndrome (GSS) 137
 glycoanalytics 127
 glycolysis 20
 Good Clinical Practice (GCP) 160, 235, 453
 good laboratory practice (GLP) 191, 194, 217, 454
 good manufacturing practice (GMP) 46, 144, 173, 191
 – compliance 227
 – computer validation 208–200
 – criteria 251
 – documentation 209–210
 – environment 446–449
 – equipment qualification 203–206
 – flow analysis 261–264
 – medicinal product 191
 – material 383
 – operative workflows 210–216
 – personnel 196–197
 – premises and equipment 198–203
 – process validation 206–208
 – production of drugs 216–217
 Good Practice rules 174
 good storage practice (GSP) 191
 granulocyte colony-stimulating factor (G-CSF) 153
 gross investments 355

h

Health Assessment Questionnaire (HAQ) 245
 heat-sterilization 54
 Herbal Medicinal Products Committee (HMPC) 231, 232
 high profitability 352
 host cell proteins (HCPs) ELISA 39, 65, 69, 95, 159, 122–123, 138, 159
 human machine interface (HMI) 429, 434
 Humira® 243, 246–247
 HVAC installations 289, 292

i

identify supplier 421
 identity testing 107

idle costs 268, 405–407, 409, 411
 immature enzymatic system 149
 immunoelectroblot 121
 immunogenicity 26, 30, 152, 156
 immunoglobulin G 26, 35
 in-house manufacturing 6, 369, 372–375
 inclusion bodies 18, 38, 44, 45, 61, 65, 66
 indirect costs 328, 408
 industrial internet of things (IIoT) 436, 438
 infrared (IR) spectroscopy 125
 integration 19, 30, 125, 271, 429, 437, 438, 440–444
 interaction criterion 61
 internal audits 178, 186
 internal rate of return 363, 366–367
 International Conference on Harmonization (ICH) 103, 113, 114, 139, 184, 185, 226, 227, 235, 237, 238, 241, 242, 399
 International Organization of Standardization (ISO) 174, 175–178, 187, 191, 197, 199, 226, 227, 237, 257, 265, 266
 International Society of Pharmaceutical Engineering (ISPE) 227, 239, 447
 intracellular expression 44, 95
 investigational drugs production 194, 216–217, 241
 Investigational Medicinal Product Dossier (IMPD) 241
 Investigational New Drug Application (IND) 241
 Investigations Operations Manual (IOM) 240
 investment appraisal
 – calculation methods 363
 – correction method 363
 – dynamic methods
 – – annuity 367
 – – capital value method 366
 – – internal rate of return 366–367
 – liquidation value 362
 – parameters of 362
 – profit 362
 – purchase price 362
 – risks and uncertainties 361–362
 – sensitivity analysis 363
 – static methods

- cost comparison 364–365
- profit comparison 365
- profitability comparison 365
- static payback time 365
- investment planning 351, 360
- investments
 - appraisal 360
 - classification of 354
 - decision processes 355–359
 - dynamic payback time 367–368
 - effect of 355
 - features of 355–356
 - life cycle of 352–353
 - targets 352–353
 - value–benefit analysis 359–360
- in vivo* gene therapy 14
- irradiation sterilization 54
- irrelevant costs 330
- Ishikawa-diagram 184, 393, 396, 400
- ISO 9000, 174–178, 187, 191, 237
- isoelectric focusing (IEF) 118, 119
- IT architecture 428, 440, 442
- IT functionalities
 - connecting 434
 - controlling 432
 - data analyzing 430
 - data storing and accessing 430
 - optimization 431–432
 - predictions 433
 - proposing 433–434
 - visualization 434
- j**
- Japanese authorities 234–235
- joint space narrowing (JSN) score
 - 244, 245
- k**
- know-how and intellectual property protection
 - 297
- l**
- labeling 35, 38, 41, 92, 99–101, 177, 184, 398
- laboratories Official Medicines Control
 - Laboratories (OMCL) 232
- laboratory execution system (LES) 436, 437, 441
- language and culture 298
- Lantus® 153
- large insulin plant (LIP) facility 272
- law book of quality assurance 178
- lean management 390, 391–392
- legal agreements 188, 309, 311, 378
- legal obligations 175, 226
- lepirudin 70, 101
- lethal dose (LD50) 152
- lethal index 152
- liability 164, 169, 175, 225, 311, 313, 315, 378
- liberation–absorption–distribution–metabolism–excretion (LADME) model
 - 145
- life-cycle projects 9
- limit of detection (LOD) 114, 128, 207
- limit of quantification (LOQ) 114, 207
- linearity 114, 207
- lipids 16, 21, 25, 31, 105, 109
- lipopolysaccharides 31, 44, 70, 109
- liquidation value 333, 362, 363, 366
- local tolerance 156
- logistics 9, 37, 100, 253, 297, 387, 437
- lower specification limit (LSL) 395, 396
- Lucentis® 247
- lyophilization cake 98, 112, 135, 153
- lyophilization process 99, 395
- m**
- Mabthera® 243–244
- make-or-buy analysis 385–387
- mammalian systems 45–46, 56
- manufacturing costs
 - cost structure 405–406
 - idle costs 407
 - product costs 407
 - unit costs 407–408
- manufacturing costs/capital costs 326
- manufacturing execution system (MES) 436, 437, 441
- manufacturing outsourcing
 - contract manufacturer 375
 - contractual agreements 377–382

- manufacturing outsourcing (*contd.*)
 - external manufacturing 375–376
 - technology transfer 382–384
 - time schedules 384–385
 - types of cooperation 376–377
 - manufacturing plant
 - cost estimates 307–309
 - cultural aspects 424–425
 - development of 416–421
 - engineering project 299–306
 - facility engineering 315–318
 - functional set-up of 416
 - organizational charts and cooperation pathways 421–423
 - project schedules 306–307
 - manufacturing process
 - cell bank 43–48
 - drug product 40–41
 - drug substance 38–40
 - formulation and filling 96–99
 - freeze-drying 98–99
 - labeling and packaging 99–101
 - process evaluation 41–43
 - purification 64–96
 - role of 35–37
 - manufacturing process changes 213–216
 - marginal costing 338, 359
 - market access 297, 359
 - mass spectrometry 117, 126–127
 - master batch record 209, 210
 - master cell bank (MCB) 47, 48, 91, 104, 106, 194, 195
 - material flows 256, 264, 432
 - matrix structure 418
 - matrix-assisted laser-desorption ionization (MALDI) 126, 127
 - maximum tolerable dose (MTD) 151, 152
 - membrane fouling 79
 - metabolism 17, 19–22, 36, 38, 43, 49, 55, 61, 62, 145, 146, 427
 - method path 105, 106
 - microbial systems
 - advantages of 45
 - disadvantage of 44
 - mammalian systems 45–46
 - transgenic systems 46
 - microorganisms 16–17, 21, 53, 55–56, 61, 71, 81, 109, 130, 132, 137, 229, 276, 280, 288
 - molecule size 73, 80, 81, 85
 - monoclonal antibodies 10, 11, 13, 28, 45, 229, 346
 - mutagenicity 156
 - mycoplasmas 17
- n**
- net investments 355
 - net present value method 366
 - Neulasta® 153
 - New Drug Application (NDA) 241
 - nominal accounting projects 327
 - nominal capacity 329, 364, 371
 - non-avoidable ADRs 165
 - non-fixed investments 353
 - non-glycosylated protein 26
 - non-secreting systems 60, 74
 - nonsegregated proteins 65
 - N-terminus 25
 - nucleic acids 16, 21, 29–30, 73, 105, 117, 118, 122, 127, 128
 - nutrient media 61, 62
- o**
- occupational health rules 317
 - Office of Regulatory Affairs (ORA) 230
 - official enforcement of regulations 239–241
 - operating costs 268, 269, 278, 299, 332, 335–338, 408
 - operational excellence
 - definition 390–391
 - example 390–391
 - lean management 391–392
 - Six-Sigma 392–396
 - organization and culture 445
 - organizational charts 186, 421–423
 - overall yield 41, 67, 95, 96, 370, 405
 - overhead calculation 327, 345
 - overhead costs 326–328, 344, 345, 348, 349, 406
- p**
- packaging materials 9, 38, 42, 99, 100, 328, 332, 399

- Paediatric Committee (PDCO) 232
- Parenteral Drug Association (PDA) 227, 239
- passive vaccination 12
- patient compliance 152, 164
- peptide mapping 117, 118
- performance management 401–403
- permitting 252, 296, 301
- personnel 196, 296
 - flow 255, 261, 262
 - training 186
- Pharmaceutical Affairs Law 226, 234
- pharmaceutical area
 - audits 186–187
 - contract review 188–189
 - documentation 180–181
 - external suppliers 187–188
 - failure prevention and correction 181–185
 - responsibility of management and training of personnel 186
- pharmaceutical bioanalytics 105
- pharmaceutical biotechnology
 - biology 16–31
 - product groups 10–16
 - production vs. development 6–8
 - production vs. marketing 8–10
 - subject areas 5
 - value chain 4
- pharmaceutical excipients 195
- Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation Scheme (PIC/S) 227
- pharmaceutical law
 - authorities of growth markets 235–236
 - bindingness of regulations 226–227
 - drug approval 241–242
 - EMA 230–233
 - FDA 228–230
 - field of 225–226
 - German Authorities 233–234
 - ICH 237, 238, 242
 - ISO 237
 - ISPE 239
 - Japanese authorities 234–235
 - official enforcement of regulations 239–241
 - PDA 239
 - PIC/S 237–239
 - US Pharmacopoeia 236–237
 - WHO 237
- pharmaceutical path 106
- Pharmaceuticals and Medical Devices Agency (PMDA) 234
- pharmacodynamics 149
 - drug effect parameters 150–152
 - principles of phenomenological effects 149–150
- pharmacokinetics 144, 145–149
- pharmacology
 - action of drugs in humans 144–152
 - drug path 162–164
 - drug study 153–162
 - route and form of administration 152–153
- pharmacovigilance 9, 10, 153, 164, 166, 167–168, 228, 232, 378
- Pharmacovigilance Agreement 378
- Pharmacovigilance Risk Assessment Committee (PRAC) 232
- phase of construction 303
- PIC/S 227, 228, 237–240
- pivotal studies 159
- planning process 6, 189, 259, 299, 301, 308, 372
- plant utilities 275–286
- plasma-desorption ionization 126
- plasmids 17–19
- polarity 73, 85
- polyclonal antibodies 12, 28
- polyethylene glycol (PEG) molecules 89, 94, 153
- Polymerase Chain Reaction (PCR) 105, 127–131
- polysaccharides 16, 21, 25, 30
- post-translational modifications 25, 26
- pre-clinical study 155–157
- precipitation 28, 65, 79, 81, 89–90, 201, 275
- precision 114, 207
- preparative criterion 61
- present values 366
- pressure drop 92, 93, 428
- primary cells 15

- process air 282–283
- process analytical technology (PAT) 438
- process analytics (IPC)
 - fermentation 132–133
 - formulation and packaging 134–135
 - purification 133–134
- process optimization 387
 - operational excellence
 - definition 390–391
 - example 390–391
 - lean management 391–392
 - Six-Sigma 392–396
- process potential 395, 396
- process validation 8, 42, 179, 180, 194, 206–208, 295, 305, 357, 361, 383
- process-capability analysis 392–394, 396
- process-capability index (C_{pk}) 395, 396
- process-oriented perspective 428
- process-related impurities 65, 69, 70, 72, 104, 106
- product analytics
 - analytical methods 115–132
 - appearance testing 112
 - biological activity 109–112
 - content 107–109
 - identity testing 107
 - purity 109
 - quality criteria of analytical methods 114–115
 - stability 112–114
- product comparability 47, 103, 138–139, 155, 216, 374
- product confusion 198, 201–203, 256
- product flow 69, 254, 261, 262, 401
- product groups
 - antibiotics 16
 - blood and organs 12–13
 - cell and gene therapeutics 13–16
 - production workflows for 11
 - recombinant therapeutic proteins 13, 14
 - vaccines 12
- product quality fluctuations 35
- product release and deviation management 211–212
- product stability 42–43
- product-related impurities 69–72, 106
- production
 - capacity planning 369–372
 - in-house manufacturing 372–375
 - make-or-buy analysis 385–387
 - manufacturing outsourcing 375–385
 - process optimization 387–396
 - supply-chain management 396–403
- production costs
 - accounting methods 338–349
 - cost calculation 327–331
 - drug life cycle 321–325
 - investment, manufacturing costs, sales, and profit 325–327
- production flow diagram 256–257
- profit and loss accounting 328, 347–349
- profit comparison 363–365
- profitability comparison 363–365
- project schedules 306–307, 369
- prokaryotic cells 17, 19, 21
- protein content 109, 117–118
- protein drugs 104, 138, 159, 243
- protein expression 43, 62
- protein products
 - Enbrel[®] 244–245
 - Humira[®] 40 mg 246–247
 - Lucentis[®] 247
 - Mabthera[®]/Rituxan[®] 243–244
 - Remicade[®] infliximab 245–246
 - Zaltrap[®] 247–248
- protein sequencing 116–117
- proteins function 25
- purification 133
 - basic pattern of 65–68
 - cell disruption, solubilization, and refolding 74–75
 - cell separation 73–74
 - chromatographic processes 81–89
 - concentration and stabilization 75–80
 - overview of 94–96
 - precipitation and extraction 89–90
 - raw materials and processing aids
 - chromatography gels 91–94
 - gels for chromatography 92
 - TFF membranes 93–94
 - separation technologies 71–73
 - sterile filtration and virus removal 90–91

- types of impurities 68–71
- pyrogen testing 129–130

q

- quadrupole MS 127
- qualify supplier 419
- qualitative side-effects 149
- quality assurance 173
 - basic principles 173–174
 - benefit of 174–175
 - development in 189–190
 - ISO 9000, 175–178
 - pharmaceutical area 180–189
 - quality management system structure 178–180
- Quality Assurance Agreement (QAA) 187, 378
- quality control (QC) 103
 - laboratories 251, 295
 - tests 209
- quality criteria of analytical methods 114–115
- quality defects 166, 169, 173, 175, 176, 178, 183, 186, 241, 391, 424
- quality management 173–189, 237
- quality management SOPs 179
- quality management system
 - pharmaceutical area 180–189
 - structure of 178–180
- quality risks 184, 185, 240, 311, 399

r

- RACI chart 419, 420
- raw material testing 103, 137–138
- raw materials and processing aids 42, 61–63, 91–94
- recombinant proteins 10, 12–14, 57
- Regulatory Procedures Manual (RPM) 240
- relevant cost 330, 348, 349, 364
- Remicade[®] infliximab 245–246
- reproductive toxicity 156
- resolution 91, 260, 312, 313, 378
- rheumatoid arthritis 244–246
- risk analysis 139, 178, 184, 285, 400
- risk–benefit ratio 143, 165
- Rituxan[®] 243–244

- robust process 42
- royalty payments 326
- Rules Governing Medicinal Products in the European Union 193

s

- SDS–PAGE 117–119
- secretion 18–19, 60
- semifinished product 38, 101, 397
- sequence ladder 129
- serialization 100, 430, 440
- serum-containing media 62
- shipping validation 207
- side-effects of drugs 143
- side-effects, causes and classification of 165–166
- single- and multiproduct plants 270–271
- Six-Sigma 391–393, 395–396
- size-exclusion chromatography (SEC) 85, 87, 92, 95, 123, 407
- small-scale model 383
- small-scale transfer 383
- social occupational safety 317
- specific SOPs 180
- specificity 114, 156, 207
- standard costing 338, 346
- standard operating procedures (SOPs) 179–181, 209, 428, 448
- static payback time 363, 365
- steel tanks and disposable equipment 274–275
- sterile filtration 54, 90–91, 97–98, 265
- sterilization (sanitization) in place (SIP) 56
- sterilization in place (SIP) 287
- sterilization methods 53
- strategy for digitalization 445
- stress stability studies 113
- subacute toxicity 156
- substance path 105
- sufficient liquidity 352
- supply contract 177, 378
- supply-chain management
 - costs of 397
 - inventory management 397
 - performance management 401–403

supply-chain management (*contd.*)
 – security of supply 398–401
 support processes 8, 416, 419, 423
 suspension culture 46, 56
 swim-lane diagram 419
 symmetry test 89
 synergies with existing facilities or units 261,
 296–297

t

tangential-flow filtration (TFF) 78–80, 93
 target-oriented leadership 391
 technical risks 311, 400
 technology transfer 357, 369, 376, 382–385
 teratogenicity 156
 therapeutic proteins 13, 19, 25, 30, 38, 40,
 229, 285
 therapeutic window 148–152
 throughput 91, 93, 401, 402
 time of flight (TOF) 127
 time schedules 299, 356, 369, 376, 384–385
 timeline risk 311
 total sharp score (TSS) 244–245
 transgenic systems 43, 46, 60–61
 transmissible spongiform encephalopathy
 (TSE) 13, 42, 62, 137
 transmission electron microscopy (TEM) 131
 transport safety 317
 triplet or codon 24

u

ultra-/diafiltration 39, 65, 72, 95
 Unified Modeling Language (UML) 419
 unit costs 101, 268, 270, 328–331, 338, 348,
 365, 407–410
 unproductive costs 407
 US Food and Drug Administration (FDA)
 214, 219, 298

US Pharmacopoeia 236–237
 UV/Vis spectroscopy 125–126

v

vaccination 12, 22
 validation runs 8, 306–307
 value engineering 308–309
 value–benefit analysis 351, 359–361
 variable costs 328–330, 406, 408, 410
 vendor-managed inventory (VMI) 398
 verum 161–162
 virus(es) 17, 22, 23, 90
 – and bacteriophages 22, 23
 – testing 130
 visual management 392
 V-model of qualification 204–205

w

waste flow 264
 waste management 254, 285–286, 316, 360
 water 275–282
 – cooling 280
 – qualities 42, 61, 62, 276–278, 281
 – users 276
 water for injection (WFI) 62, 98, 254,
 277–284, 287–288, 294
 western blotting 121
 wet AMD 247
 working cell banks (WCBs) 48, 106, 194
 World Health Organization (WHO) 227, 235,
 237, 240

z

Zaltrap® 243, 247–248
 zero-defect approach 391
 zoning concept 255, 259, 264–267

